Final analysis of the ELIXIR study: A prospective, multicenter, observational study to evaluate the efficacy and safety of atezolizumab plus bevacizumab (Atezo plus Bev) in Japanese patients with unresectable hepatocellular carcinoma (uHCC) in a real-world clinical setting

被引：0

作者：

Takehara, T. ^{[1
]}

Kato, N. ^{[2
]}

Aikata, H. ^{[3
]}

Kuzuya, T. ^{[4
]}

Hiasa, Y. ^{[5
]}

Nakamura, S. ^{[6
]}

Yamamoto, K. ^{[7
]}

Morimoto, N. ^{[8
]}

Sakamori, R. ^{[9
]}

Kawamura, Y. ^{[10
]}

Tsuchiya, K. ^{[11
]}

Ueshima, K. ^{[12
]}

Hiraoka, A. ^{[13
]}

Nakano, M. ^{[14
]}

Kokudo, N. ^{[15
]}

Furuse, J. ^{[16
]}

Moriguchi, M. ^{[17
]}

Yamashita, T. ^{[18
]}

Ikeda, M. ^{[19
]}

Kudo, M. ^{[12
]}

机构：

[1] Osaka Univ, Grad Sch Med, Gastroenterol & Hepatol, Osaka, Japan

[2] Chiba Univ, Sch Med, Gastroenterol, Chiba, Japan

[3] Hiroshima Prefectural Hosp, Gastroenterol, Hiroshima, Japan

[4] Fujita Hlth Univ, Dept Gastroenterol & Hepatol, Toyoake, Aichi, Japan

[5] Ehime Univ, Grad Sch Med, Gastroenterol & Metabol, Matsuyama, Ehime, Japan

[6] Japanese Red Cross Soc Himeji Hosp, Internal Med, Himeji, Hyogo, Japan

[7] Yokohama City Univ, Sch Med, Dept Biostat, Yokohama, Kanagawa, Japan

[8] Jichi Med Univ Hosp, Dept Gastroenterol, Shimotsuke, Tochigi, Japan

[9] Natl Hosp Org Osaka Natl Hosp, Gastroenterol & Hepatol, Osaka, Japan

[10] Toranomon Gen Hosp, Hepatol, Tokyo, Japan

[11] Musashino Red Cross Hosp, Dept Gastroenterol & Hepatol, Tokyo, Japan

[12] Kindai Univ, Fac Med, Gastroenterol & Hepatol, Osaka, Japan

[13] Ehime Prefectural Cent Hosp, Gastroenterol, Matsuyama, Ehime, Japan

[14] Kurume Univ, Sch Med, Dept Med, Div Gastroenterol, Fukuoka, Japan

[15] NCGM Natl Ctr Global Hlth & Med, Surg, Tokyo, Japan

[16] Kanagawa Canc Ctr, Dept Gastroenterol, Yokohama, Kanagawa, Japan

[17] Kyoto Prefectural Univ Med, Mol Gastroenterol & Hepatol, Kyoto, Japan

[18] Kanazawa Univ Hosp, Gastroenterol Dept, Kanazawa, Ishikawa, Japan

[19] Natl Canc Ctr Hosp East, Hepatobiliary & Pancreat Oncol Dept, Chiba, Japan

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.10.221

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

200P

引用

页码：S1480 / S1481

页数：2

共 50 条

[1] Safety and efficacy of atezolizumab (Atezo) plus bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)
Kuzuya, T.
Yamashita, T.
Takehara, T.
Aikata, H.
Kato, N.
Hiasa, Y.
Nakamura, S.
Morimoto, N.
Moriguchi, M.
Ikeda, M.
Inoue, J.
Tani, J.
Ueno, Y.
Chayama, K.
Tateishi, R.
Kawamura, Y.
Furuse, J.
Kudo, M.
Yamamoto, K.
Kokudo, N.
ANNALS OF ONCOLOGY, 2023, 34 : S1531 - S1532
[2] Safety and efficacy of atezolizumab (Atezo) plus bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): A prospective, multicenter, observational study (ELIXIR) - A preliminary analysis
Ikeda, M.
Kato, N.
Kagawa, T.
Yamashita, T.
Moriguchi, M.
Nakamura, S.
Sawada, K.
Iijima, H.
Kamoshida, T.
Nakao, K.
Ohkawa, K.
Sugimoto, R.
Takehara, T.
Harada, M.
Yamamoto, Y.
Ito, T.
Kudo, M.
Kokudo, N.
Yamamoto, K.
Furuse, J.
ANNALS OF ONCOLOGY, 2022, 33 : S1467 - S1467
[3] Association of skeletal muscle mass with safety and efficacy of atezolizumab (atezo) plus bevacizumab (bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Results from the ELIXIR study
Hiraoka, A.
Aikata, H.
Moriguchi, M.
Ikeda, M.
Morimoto, N.
Tsuchiya, K.
Takehara, T.
Nagai, H.
Sakamori, R.
Nakamura, S.
Tsuji, K.
Kuroda, H.
Shimizu, M.
Shiina, S.
Yamasaki, T.
Kudo, M.
Kokudo, N.
Furuse, J.
Yamamoto, K.
Yamashita, T.
ANNALS OF ONCOLOGY, 2024, 35 : S660 - S661
[4] Effectiveness and safety of atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: A multicenter, retrospective real-world study in China
Zhang, Hui
Shao, Minghua
Tan, Binbin
Fu, Yin
Yuan
Chen, Hailei
CANCER RESEARCH, 2024, 84 (06)
[5] Clinical factors associated with the therapeutic efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter prospective observational study
Kai, Machiko
Hikita, Hayato
Kazuki, Maesaka
Tahata, Yuki
Shinkai, Kazuma
Doi, Akira
Ohkawa, Kazuyoshi
Miyazaki, Masanori
Ishida, Hisashi
Matsumoto, Kengo
Nozaki, Yasutoshi
Yakushijin, Takayuki
Sakamori, Ryotaro
Kaneko, Akira
Iio, Sadaharu
Nawa, Takatoshi
Kakita, Naruyasu
Morishita, Naoki
Hiramatsu, Naoki
Usui, Takeo
Imanaka, Kazuho
Doi, Yoshinori
Sakakibara, Mitsuru
Yoshida, Yuichi
Oze, Tsugiko
Kodama, Takahiro
Tatsumi, Tomohide
Takehara, Tetsuo
PLOS ONE, 2024, 19 (01):
[6] CLINICAL FACTORS ASSOCIATED WITH THE THERAPEUTIC EFFICACY OF ATEZOLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA: A MULTICENTER PROSPECTIVE OBSERVATIONAL STUDY
Maesaka, Kazuki
Hikita, Hayato
Kai, Machiko
Tahata, Yuki
Shinkai, Kazuma
Doi, Akira
Ohkawa, Kazuyoshi
Miyazaki, Masanori
Ishida, Hisashi
Matsumoto, Kengo
Nozaki, Yasutoshi
Yakushijin, Takayuki
Sakamori, Ryotaro
Kodama, Takahiro
Tatsumi, Tomohide
Takehara, Tetsuo
HEPATOLOGY, 2023, 78 : S1813 - S1813
[7] Retrospective study of the correlation between proteinuria and renal function in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with atezolizumab plus bevacizumab (Atezo plus Bev): ARISE study
Ueshima, K.
Nishida, N.
Hagihara, S.
Minami, Y.
Ida, H.
Takita, M.
Chishina, H.
Morita, M.
Aoki, T.
Kudo, M.
ANNALS OF ONCOLOGY, 2023, 34 : S1542 - S1542
[8] Disease etiology and efficacy outcomes with atezolizumab plus bevacizumab (atezo-bev) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Multinational retrospective analysis
Kim, S.
Lee, S. Y.
Park, Y. G.
Kim, H-D.
Lee, J. J. X.
Ryu, M. H.
Ryoo, B-Y.
Tai, D. W. M.
Yoo, C.
ANNALS OF ONCOLOGY, 2023, 34 : S609 - S610
[9] The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey
Akyildiz, Arif
Guven, Deniz Can
Ozluk, Ahmet Anil
Ismayilov, Rashad
Mutlu, Emel
Unal, Olcun Umit
Yildiz, Ibrahim
Iriagac, Yakup
Turhal, Serdar
Akbas, Sinem
Bayram, Ertugrul
Telli, Tugba Akin
Turkoz, Fatma Paksoy
Ozcelik, Melike
Erciyestepe, Mert
Selvi, Oguzhan
Gulbagci, Burcu
Erturk, Ismail
Isleyen, Zehra Sucuoglu
Kahraman, Seda
Akdag, Mutianur Ozkorkmaz
Hamitoglu, Buket
Unek, Ilkay Tugba
Unal, Caglar
Hacibekiroglu, Ilhan
Arslan, Cagatay
Azizy, Abdulmunir
Helvaci, Kaan
Demirci, Umut
Dizdar, Omer
Basaran, Mert
Goker, Erdem
Sendur, Mehmet Ali
Yalcin, Suayib
MEDICINE, 2023, 102 (45) : E35950
[10] Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study
Mara Persano
Margherita Rimini
Toshifumi Tada
Goki Suda
Shigeo Shimose
Masatoshi Kudo
Jaekyung Cheon
Fabian Finkelmeier
Ho Yeong Lim
Lorenza Rimassa
José Presa
Gianluca Masi
Changhoon Yoo
Sara Lonardi
Francesco Tovoli
Takashi Kumada
Naoya Sakamoto
Hideki Iwamoto
Tomoko Aoki
Hong Jae Chon
Vera Himmelsbach
Tiziana Pressiani
Takumi Kawaguchi
Margarida Montes
Caterina Vivaldi
Caterina Soldà
Fabio Piscaglia
Atsushi Hiraoka
Takuya Sho
Takashi Niizeki
Naoshi Nishida
Christoph Steup
Massimo Iavarone
Giovanni Di Costanzo
Fabio Marra
Mario Scartozzi
Emiliano Tamburini
Giuseppe Cabibbo
Francesco Giuseppe Foschi
Marianna Silletta
Masashi Hirooka
Kazuya Kariyama
Joji Tani
Masanori Atsukawa
Koichi Takaguchi
Ei Itobayashi
Shinya Fukunishi
Kunihiko Tsuji
Toru Ishikawa
Kazuto Tajiri
Journal of Cancer Research and Clinical Oncology, 2023, 149 : 5591 - 5602

← 1 2 3 4 5 →